Muscle and Bone Impairment in Children with Marfan Syndrome: Correlation with Age and FBN1 Genotype

Journal of Bone and Mineral Research

Volumn 30, Issue 8, 2015, Pages 1369-1376

  Haine, Elsa ^a   Salles, Jean Pierre ^a,b   Khau Van Kien, Philippe ^c   Conte Auriol, Françoise ^a,b   Gennero, Isabelle ^a,b   Plancke, Aurélie ^c   Julia, Sophie ^a   Dulac, Yves ^a   Tauber, Maithé ^a,b   Edouard, Thomas ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b France   (France)

^c CHU Carémeau ^*  (France)

Author keywords

BONE MINERAL DENSITY; DXA; FIBRILLIN 1; MARFAN SYNDROME; PUBERTY; TGF

Indexed keywords

FIBRILLIN 1; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D; ACTIN BINDING PROTEIN; FIBRILLIN; STOP CODON;

ADOLESCENT; ADULT; AGE; ARTICLE; BONE DENSITY; BONE DISEASE; BONE MASS; BONE MINERAL; CHILD; CODON; CONTROLLED STUDY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FBN1 GENE; FEMALE; GENE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPOPLASIA; LEAN BODY WEIGHT; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MARFAN SYNDROME; MUSCLE DISEASE; MUSCLE MASS; OSTEOLYSIS; SIGNAL TRANSDUCTION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; YOUNG ADULT; AGING; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; FOLLOW UP; GENETICS; GENOTYPE; PATHOLOGY; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PRESCHOOL CHILD; RADIOGRAPHY; SKELETAL MUSCLE; SPINE; STOP CODON;

ABSORPTIOMETRY, PHOTON; ADULT; AGING; BONE DENSITY; CHILD; CHILD, PRESCHOOL; CODON, TERMINATOR; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MARFAN SYNDROME; MICROFILAMENT PROTEINS; MUSCLE, SKELETAL; SPINE;

EID: 84937164400     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2471     Document Type: Article

References (50)

1. Judge DP, Dietz HC., Marfan's syndrome. Lancet. 2005; 366 (9501): 1965-76.
2. Ramirez F, Dietz HC., Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr Opin Genet Dev. 2007; 17 (3): 252-8.
3. Habashi JP, Judge DP, Holm TM, et al., Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006; 312 (5770): 117-21.
4. Lacro RV, Guey LT, Dietz HC, et al., Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. Am Heart J. 2013; 165 (5): 828-35. e3.
5. Loeys BL, Mortier G, Dietz HC., Bone lessons from Marfan syndrome and related disorders: fibrillin, TGF-β and BMP at the balance of too long and too short. Pediatr Endocrinol Rev. 2013; 10 (Suppl 2): 417-23.
6. Carter N, Duncan E, Wordsworth P., Bone mineral density in adults with Marfan syndrome. Rheumatology (Oxford). 2000; 39 (3): 307-9.
7. Giampietro PF, Peterson M, Schneider R, et al., Assessment of bone mineral density in adults and children with Marfan syndrome. Osteoporos Int. 2003; 14 (7): 559-63.
8. Giampietro PF, Peterson MG, Schneider R, et al., Bone mineral density determinations by dual-energy x-ray absorptiometry in the management of patients with Marfan syndrome-some factors which affect the measurement. HSS J. 2007; 3 (1): 89-92.
9. Kohlmeier L, Gasner C, Bachrach LK, Marcus R., The bone mineral status of patients with Marfan syndrome. J Bone Miner Res. 1995; 10 (10): 1550-5.
10. Kohlmeier L, Gasner C, Marcus R., Bone mineral status of women with Marfan syndrome. Am J Med. 1993; 95 (6): 568-72.
11. Le Parc JM, Plantin P, Jondeau G, Goldschild M, Albert M, Boileau C., Bone mineral density in sixty adult patients with Marfan syndrome. Osteoporos Int. 1999; 10 (6): 475-9.
12. Moura B, Tubach F, Sulpice M, et al., Bone mineral density in Marfan syndrome. A large case-control study. Joint Bone Spine. 2006; 73 (6): 733-5.
13. Tobias JH, Dalzell N, Child AH., Assessment of bone mineral density in women with Marfan syndrome. Br J Rheumatol. 1995; 34 (6): 516-9.
14. Grover M, Brunetti-Pierri N, Belmont J, et al., Assessment of bone mineral status in children with Marfan syndrome. Am J Med Genet A. 2012; 158A (9): 2221-4.
15. Schonau E., Problems of bone analysis in childhood and adolescence. Pediatr Nephrol. 1998; 12 (5): 420-9.
16. Loeys BL, Dietz HC, Braverman AC, et al., The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010; 47 (7): 476-85.
17. Gautier M, Detaint D, Fermanian C, et al., Nomograms for aortic root diameters in children using two-dimensional echocardiography. Am J Cardiol. 2010; 105 (6): 888-94.
18. Mellerio H, Alberti C, Druet C, et al., Novel modeling of reference values of cardiovascular risk factors in children aged 7 to 20 years. Pediatrics. 2012; 129 (4): e1020-9.
19. Fischer DC, Mischek A, Wolf S, et al., Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem. 2012; 49 (Pt 6): 546-53.
20. Khau Van Kien P, Baux D, Pallares-Ruiz N, et al., Missense mutations of conserved glycine residues in fibrillin-1 highlight a potential subtype of cb-EGF-like domains. Hum Mutat. 2010; 31 (1): E1021-42.
21. Thodberg HH, van Rijn RR, Tanaka T, Martin DD, Kreiborg S., A paediatric bone index derived by automated radiogrammetry. Osteoporos Int. 2010; 21 (8): 1391-400.
22. Kroger H, Vainio P, Nieminen J, Kotaniemi A., Comparison of different models for interpreting bone mineral density measurements using DXA and MRI technology. Bone. 1995; 17 (2): 157-9.
23. van der Sluis IM, de Ridder MA, Boot AM, Krenning EP, de Muinck Keizer-Schrama SM,. Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults. Arch Dis Child. 2002; 87 (4): 341-7; discussion 341-7.
24. Bowden SA, Robinson RF, Carr R, Mahan JD,. Prevalence of vitamin D deficiency and insufficiency in children with osteopenia or osteoporosis referred to a pediatric metabolic bone clinic. Pediatrics. 2008; 121 (6): 31585-90.
25. Edouard T, Glorieux FH, Rauch F., Predictors and correlates of vitamin D status in children and adolescents with osteogenesis imperfecta. J Clin Endocrinol Metab. 2011; 96 (10): 3193-8.
26. Mallet E, Gaudelus J, Reinert P, et al., [Vitamin D status in 6- to 10-year-old children: A French multicenter study in 326 children]. Arch Pediatr. 2014; 21 (10): 1106-14.
27. Vierucci F, Del Pistoia M, Fanos M, et al., Vitamin D status and predictors of hypovitaminosis D in Italian children and adolescents: a cross-sectional study. Eur J Pediatr. 2013; 172 (12): 1607-17.
28. Mark S, Gray-Donald K, Delvin EE, et al., Low vitamin D status in a representative sample of youth from Quebec, Canada. Clin Chem. 2008; 54 (8): 1283-9.
29. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M., Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008; 122 (2): 398-417.
30. Lehtonen-Veromaa MK, Mottonen TT, Nuotio IO, Irjala KM, Leino AE, Viikari JS,. Vitamin D and attainment of peak bone mass among peripubertal Finnish girls: a 3-y prospective study. Am J Clin Nutr. 2002; 76 (6): 1446-53.
31. El-Hajj Fuleihan G, Nabulsi M, Tamim H, et al., Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab. 2006; 91 (2): 405-12.
32. Stagi S, Cavalli L, Iurato C, Seminara S, Brandi ML, de Martino M., Bone metabolism in children and adolescents: main characteristics of the determinants of peak bone mass. Clin Cases Miner Bone Metab. 2013; 10 (3): 172-9.
33. Schrijver I, Liu W, Odom R, et al., Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes. Am J Hum Genet. 2002; 71 (2): 223-37.
34. Faivre L, Collod-Beroud G, Loeys BL, et al., Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet. 2007; 81 (3): 454-66.
35. Ben Amor IM, Edouard T, Glorieux FH, et al., Low bone mass and high material bone density in two patients with Loeys-Dietz syndrome caused by transforming growth factor beta receptor 2 mutations. J Bone Miner Res. 2012; 27 (3): 713-8.
36. Kirmani S, Tebben PJ, Lteif AN, et al., Germline TGF-beta receptor mutations and skeletal fragility: a report on two patients with Loeys-Dietz syndrome. Am J Med Genet A. 2010; 152A (4): 1016-9.
37. Nistala H, Lee-Arteaga S, Carta L, et al., Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. Hum Mol Genet. 2010; 19 (24): 4790-8.
38. Kuchuk NO, van Schoor NM, Pluijm SM, Chines A, Lips P., Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective. J Bone Miner Res. 2009; 24 (4): 693-701.
39. Mohammad KS, Chen CG, Balooch G, et al., Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PloS One. 2009; 4 (4): e5275.
40. Balooch G, Balooch M, Nalla RK, et al., TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci USA. 2005; 102 (52): 18813-8.
41. Neu CM, Rauch F, Rittweger J, Manz F, Schoenau E., Influence of puberty on muscle development at the forearm. Am J Physiol Endocrinol Metab. 2002; 283 (1): E103-7.
42. Behan WM, Longman C, Petty RK, et al., Muscle fibrillin deficiency in Marfan's syndrome myopathy. J Neurol Neurosurg Psychiatry. 2003; 74 (5): 633-8.
43. Giske L, Stanghelle JK, Rand-Hendrikssen S, Strom V, Wilhelmsen JE, Roe C., Pulmonary function, working capacity and strength in young adults with Marfan syndrome. J Rehabil Med. 2003; 35 (5): 221-8.
44. Percheron G, Fayet G, Ningler T, et al., Muscle strength and body composition in adult women with Marfan syndrome. Rheumatology (Oxford). 2007; 46 (6): 957-62.
45. Jadro-Santel D, Grcevic N, Dogan S, Franjic J, Benc H., Centronuclear myopathy with type I fibre hypotrophy and "fingerprint" inclusions associated with Marfan's syndrome. J Neurol Sci. 1980; 45 (1): 43-56.
46. Cohn RD, van Erp C, Habashi JP, et al., Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med. 2007; 13 (2): 204-10.
47. Burks TN, Andres-Mateos E, Marx R, et al., Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med. 2011; 3 (82): 82ra37.
48. Peters KF, Horne R, Kong F, Francomano CA, Biesecker BB., Living with Marfan syndrome II. Medication adherence and physical activity modification. Clin Genet. 2001; 60 (4): 283-92.
49. Frost HM,. Perspective: genetic and hormonal roles in bone disorders: insights of an updated bone physiology. J Musculoskelet Neuronal Interact. 2003; 3 (2): 118-35.
50. Lacro RV, Dietz HC, Sleeper LA, et al., Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014; 371 (22): 2061-71.